CARVEDILOL
Clinical safety rating: caution
Animal studies have proved adverse effects but may be safe for humans
Carvedilol is a nonselective beta-adrenergic receptor antagonist (beta-1, beta-2) and alpha-1 adrenergic receptor antagonist. It causes vasodilation and reduces heart rate, myocardial contractility, and blood pressure. It also has antioxidant and anti-proliferative effects.
| Metabolism | Extensively metabolized in the liver primarily by CYP2D6 and CYP2C9, with minor contributions from other CYP enzymes. Undergoes aromatic ring oxidation and glucuronidation. Bioavailability is about 25-35% due to first-pass metabolism. |
| Excretion | Primarily hepatic metabolism, with less than 2% excreted unchanged in urine. Metabolites are excreted in bile and feces; renal clearance of metabolites accounts for ~16% of total clearance. Fecal excretion of metabolites is ~60%. |
| Half-life | Terminal elimination half-life is 7-10 hours. Steady-state concentrations are achieved within 2-3 days. Clinical context: Twice-daily dosing provides consistent beta-blockade and vasodilation. |
| Protein binding | 98% bound, primarily to albumin. |
| Volume of Distribution | 1.5 L/kg (range 1.2-2.0 L/kg). This large Vd indicates extensive tissue distribution, including cardiac and vascular tissues. |
| Bioavailability | Oral bioavailability is 25-35% due to extensive first-pass metabolism. Administration with food delays absorption but does not affect overall bioavailability. Note: Bioavailability increases with chronic dosing due to saturation of hepatic extraction. |
| Onset of Action | Oral: Within 30 minutes for beta-blockade; peak hemodynamic effects occur at 1-2 hours. Intravenous: Not available in standard formulations. |
| Duration of Action | Beta-blockade lasts 12-24 hours, supporting twice-daily dosing. Antihypertensive effect persists for 24 hours with sustained BP reduction. Clinical note: Titration to target dose may take weeks due to dose-dependent effects. |
Heart failure: Initial 3.125 mg orally twice daily, titrate every 2 weeks to 6.25 mg, 12.5 mg, then 25 mg twice daily as tolerated. Target dose: 25 mg twice daily (≤85 kg) or 50 mg twice daily (>85 kg). Hypertension: Initial 6.25 mg orally twice daily, titrate every 1-2 weeks to 12.5 mg, then 25 mg twice daily. Maximum: 50 mg twice daily.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for renal impairment. Use caution in severe renal impairment; monitor blood pressure and heart rate. |
| Liver impairment | Contraindicated in Child-Pugh class B and C (moderate to severe hepatic impairment). Use with caution in mild impairment; initial dose should not exceed 3.125 mg twice daily. |
| Pediatric use | Not FDA-approved for pediatric hypertension. Limited data: For heart failure (>18 years), dosing as per adult; no standard weight-based pediatric dosing established. In clinical studies, initial 0.1 mg/kg/dose orally twice daily (max 6.25 mg), titrated to target of 0.3-0.5 mg/kg/dose twice daily (max 25 mg). |
| Geriatric use | Start at low end of dosing range (3.125 mg twice daily for heart failure; 6.25 mg twice daily for hypertension). Titrate slowly with close monitoring of blood pressure and heart rate due to increased risk of hypotension and bradycardia. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Other drugs that lower heart rate or blood pressure can have additive effects Abrupt withdrawal may exacerbate angina pectoris or cause myocardial infarction.
| Breastfeeding | Carvedilol is excreted into breast milk in low amounts (estimated M/P ratio ~1.5). Infant exposure is minimal but may cause bradycardia or hypotension. Use with caution, especially in preterm infants or those with renal impairment. |
| Teratogenic Risk | First trimester: Limited data; no evidence of major malformations in human studies, but beta-blockers may cause fetal bradycardia and hypoglycemia. Second/third trimester: Risk of intrauterine growth restriction, reduced placental weight, and perinatal complications (bradycardia, hypotension, hypoglycemia). Avoid in pregnancy unless benefit outweighs risk. |
■ FDA Black Box Warning
None
| Common Effects | heart failure |
| Serious Effects |
["Bronchial asthma or related bronchospastic conditions","Decompensated heart failure requiring intravenous inotropic therapy","Sick sinus syndrome or severe bradycardia (unless pacemaker present)","Cardiogenic shock","Severe hepatic impairment","Hypersensitivity to carvedilol or any component"]
| Precautions | ["May mask symptoms of hypoglycemia and hyperthyroidism","May worsen peripheral vascular disease","Avoid abrupt discontinuation (taper over 1-2 weeks)","Use caution in patients with bronchospastic disease","Monitor for worsening heart failure or fluid retention","May cause bradycardia and hypotension","Use with caution in patients with hepatic impairment"] |
| Food/Dietary |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure and heart rate regularly. Assess fetal growth via ultrasound (every 4-6 weeks) due to potential intrauterine growth restriction. Neonatal monitoring for bradycardia, hypotension, and hypoglycemia after delivery. |
| Fertility Effects | No human data on fertility effects. In animal studies, no adverse effects on fertility were observed. Theoretical risk of reduced uterine blood flow may impact implantation, but not established. |
| Take with food to minimize orthostatic hypotension. Avoid alcohol, as it may increase blood pressure-lowering effects and dizziness. |
| Clinical Pearls | Carvedilol is a non-selective beta-blocker with alpha-1 blocking activity, reducing both heart rate and peripheral vascular resistance. It is indicated for heart failure with reduced ejection fraction (HFrEF) and hypertension. Dosing must be initiated at low doses (3.125 mg twice daily) and titrated slowly to avoid hypotension. Monitor for bradycardia, dizziness, and fluid retention. Avoid abrupt discontinuation; taper over 1-2 weeks. Carvedilol may mask hypoglycemia symptoms in diabetic patients. Use caution in asthma or COPD due to bronchospasm risk. |
| Patient Advice | Take carvedilol with food to slow absorption and reduce dizziness. · Do not stop taking this medication suddenly; sudden stop can cause chest pain or heart attack. · May cause dizziness or lightheadedness, especially when standing up; rise slowly from sitting or lying positions. · If you have diabetes, monitor blood sugar closely as carvedilol may mask signs of low blood sugar. · Do not take over-the-counter decongestants or NSAIDs without consulting your doctor. · Attend regular follow-up appointments to monitor heart function and adjust dose. |